Characterizing uncertainty in the assessment of benefits and risks of pharmaceutical products
On February 12, 2014, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop as the first of a two-part series to advance the development of more systematic and structured approaches to characterize and communicate the sources of uncertainty in...
Main Author: | |
---|---|
Corporate Authors: | , , |
Other Authors: | |
Format: | eBook |
Language: | English |
Published: |
[Washington, DC]
Institute of Medicine of the National Academies Press
2014, April 2014
|
Series: | Workshop in brief
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | On February 12, 2014, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop as the first of a two-part series to advance the development of more systematic and structured approaches to characterize and communicate the sources of uncertainty in the assessment of benefits and risks, as well as their implications for pharmaceutical regulatory decisions. Workshop presentations and discussions were convened to explore the science of identifying and characterizing uncertainty in scientific evidence and approaches to translate uncertainties into decisions that reflect the values of stakeholders. This brief summary of the workshop provides highlights from the presentations and discussions |
---|---|
Physical Description: | 1 PDF file (7 pages) |